The Influence of Iron-Deficiency Anaemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consumptions in Chronic Kidney Disease Patients Affected by IDA: A Real-Word Evidence Study among the Italian Population

The Influence of Iron-Deficiency Anaemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consumptions in Chronic Kidney Disease Patients Affected by IDA: A Real-Word Evidence Study among the Italian Population

Anaemia is a uraemia-related complication frequently found in non-dialysis-dependent chronic kidney disease (ND-CKD) patients, with iron-deficiency anaemia (IDA) as the main underlying mechanism. Given the suboptimal anaemia management in ND-CKD patients with a co-diagnosis of IDA, this study evalua...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine Vol. 11; no. 19; p. 5820
Main Authors: Perrone, Valentina, Veronesi, Chiara, Dovizio, Melania, Ancona, Domenica Daniela, Bartolini, Fausto, Ferrante, Fulvio, Lupi, Alessandro, Palcic, Stefano, Re, Davide, Terlizzi, Annamaria Pia, Ramirez de Arellano Serna, Antonio, Cogliati, Paolo, Degli Esposti, Luca
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 30-09-2022
MDPI
Subjects:
Anemia
Chronic obstructive pulmonary disease
Clinical medicine
Clinical outcomes
Codes
Costs
Hemodialysis
Hospitalization
Iron
Kidney diseases
Mortality
Patients
Prescriptions
Quality of life
Tariffs
IDA therapy
iron-deficiency anaemia (IDA)
non-dialysis-dependent chronic kidney disease patients (ND-CKD)
direct healthcare costs
real-world data analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anaemia is a uraemia-related complication frequently found in non-dialysis-dependent chronic kidney disease (ND-CKD) patients, with iron-deficiency anaemia (IDA) as the main underlying mechanism. Given the suboptimal anaemia management in ND-CKD patients with a co-diagnosis of IDA, this study evaluated the role of IDA therapy on clinical outcomes and healthcare resource consumptions in an Italian clinical setting. A retrospective observational real-world analysis was performed on administrative databases of healthcare entities, covering around 6.9 million health-assisted individuals. From January 2010 to March 2019, ND-CKD patients were included and diagnosed with IDA in the presence of two low-haemoglobin (Hb) measurements. Patients were divided into IDA-treated and untreated, based on the prescription of iron [Anatomical-Therapeutic Chemical (ATC) code B03A] or anti-anaemia preparations (ATC code B03X), and evaluated during a 6-month follow-up from the index date [first low haemoglobin (Hb) detection]. IDA treatment resulted in significantly decreased incidence of all cause-related, cardiovascular-related, and IDA-related hospitalizations (treated vs. untreated: 44.5% vs. 81.8%, 12.3% vs. 25.3%, and 16.2% vs. 26.2%, respectively, p < 0.001). A healthcare direct cost estimation showed that overall mean expenditure per patient reduced by 47% with IDA treatment (5245€ vs. 9918€, p < 0.001), mainly attributable to hospitalizations (3767€ vs. 8486€, p < 0.001). This real-life analysis on Italian ND-CKD-IDA patients indicates that IDA therapy administration provides significant benefits in terms of patients’ clinical outcomes and healthcare cost savings.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11195820